AI-generated research brief — verify at source
Belatacept Shows No Increased CMV or EBV-PTLD Risk in RCTs, but Real-World Data Suggest Higher Viral Infection Rates
In a meta-analysis of 64 studies, belatacept was not associated with significantly elevated CMV or EBV-related post-transplant lymphoproliferative disease risk compared to calcineurin inhibitors in randomised controlled trial data, but non-randomised real-world studies found more than two-fold higher CMV risk (RR 2.15, 95% CI 1.58–2.93) and over two-fold higher BK polyomavirus risk (RR 2.59, 95% CI 1.10–6.11) among belatacept-treated kidney transplant recipients. A notable internal discrepancy between controlled trial and real-world findings introduces meaningful uncertainty about the true viral infection burden attributable to belatacept.
What Was Studied
This review examined whether belatacept — used as an alternative immunosuppressive regimen to calcineurin inhibitors in kidney transplantation — carries an elevated long-term risk of three clinically significant viral complications: cytomegalovirus (CMV) infection, BK polyomavirus infection or DNAemia, and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD). Understanding this risk profile across both dosing intensities and follow-up durations is essential for informing immunosuppression selection after kidney transplantation.
How It Was Studied
Researchers conducted a systematic review and meta-analysis by searching multiple databases from inception through September 2025 using terms related to belatacept, kidney transplantation, safety, and viral infection. A total of 64 studies were included — 23 randomised controlled trials (RCTs), 28 non-randomised trials (NRTs), and 13 case reports — covering kidney transplant recipients receiving either belatacept (at more-intense or less-intense dosing) or calcineurin inhibitors (CNIs) as comparators. RCTs and NRTs were analysed separately, and outcomes were stratified by infection type and follow-up period: short-term (1–2 years), medium-term (3–5 years), and long-term (beyond 5 years). Binary outcomes were expressed as risk ratios (RR) with 95% confidence intervals, and analyses were performed using RevMan 5.2.
What Was Observed
- No significant difference in CMV or EBV-PTLD risk in RCTs: Across RCT meta-analyses, the risks of CMV infection and EBV-associated PTLD were statistically similar between belatacept-treated patients and those receiving CNIs at all follow-up time points examined.
- Higher BK virus risk with more-intense belatacept dosing in RCTs: During medium-term follow-up (3–5 years), patients receiving more-intense belatacept were approximately twice as likely to develop BK virus infection compared to those on less-intense dosing — about double the risk (RR 2.08, 95% CI 1.03–4.20, I²=0%), a finding with no statistical heterogeneity across contributing studies.
- More than two-fold higher CMV risk in real-world NRT data: Non-randomised studies found belatacept associated with substantially higher CMV infection rates compared to CNIs — roughly double the risk (RR 2.15, 95% CI 1.58–2.93, I²=66%), though considerable heterogeneity across NRTs limits confidence in this estimate.
- More than two-fold higher BK DNAemia or viremia risk in NRTs: Real-world non-randomised data also showed a markedly elevated BK polyomavirus burden among belatacept recipients relative to CNI-treated patients — more than two-and-a-half times the risk (RR 2.59, 95% CI 1.10–6.11), though the wide confidence interval indicates imprecision in this estimate.
Why This Matters
The divergence between RCT findings and real-world NRT results raises important questions about whether trial conditions adequately capture the viral infection risks that emerge in routine clinical practice. The identification of a dose-dependent BK polyomavirus signal within RCT data specifically beyond the second post-transplant year suggests that immunosuppression intensity and duration both influence infectious risk, not simply the choice of agent. These findings highlight the relevance of long-term viral surveillance and careful dose selection when belatacept is used as an immunosuppressive strategy following kidney transplantation.
How to Read This Result
The overall confidence in these conclusions is moderate at best: the discordance between RCT and NRT findings, substantial heterogeneity in the NRT CMV analysis (I²=66%), and the inherent susceptibility of non-randomised studies to confounding and selection bias collectively mean that the magnitude of belatacept-associated viral infection risk in real-world settings remains uncertain.
Limitations
Non-randomised trials are inherently vulnerable to confounding and selection bias, and the authors explicitly caution that NRT findings should not be interpreted equivalently to RCT evidence. Significant heterogeneity was present in the NRT CMV pooled estimate (I²=66%), which reduces the reliability of that specific finding. Follow-up durations varied considerably across the 64 included studies, which complicates direct comparisons across time strata and may obscure late-emerging viral risks.